@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix isothes: <http://purl.org/iso25964/skos-thes#> .

<https://concepts.sagepub.com/social-science/concept/drug_classification>
  skos:prefLabel "drug classification"@en ;
  a skos:Concept ;
  skos:narrower <https://concepts.sagepub.com/social-science/concept/levo-alpha_acetyl_methadol> .

<https://concepts.sagepub.com/social-science/concept/conceptgroup/concepts>
  a skos:Collection, isothes:ConceptGroup ;
  skos:prefLabel "concepts"@en ;
  skos:member <https://concepts.sagepub.com/social-science/concept/levo-alpha_acetyl_methadol> .

<https://concepts.sagepub.com/social-science/concept/levo-alpha_acetyl_methadol>
  skos:definition "There are currently three Food and Drug Administration (FDA)-approved opioid agonist treatments for opioid addiction, which include methadone hydrochloride, buprenorphine hydrochloride, and levo-alpha acetyl methadol (LAAM). All three of these drugs are long-acting opioids, which bind to opioid receptors and thus block opioids from binding to these receptors. [Source: <a href=\"https://sk.sagepub.com/reference/substance/n205.xml\" target=\"_blank\" data-id=\"to-sk\">Encyclopedia of Substance Abuse Prevention, Treatment, &amp; Recovery; Levo-Alpha Acetyl Methadol</a>]"@en ;
  skos:broader <https://concepts.sagepub.com/social-science/concept/treatment_theories,_research,_techniques,_strategies,_and_effectiveness>, <https://concepts.sagepub.com/social-science/concept/drug_classification> ;
  skos:prefLabel "levo-alpha acetyl methadol"@en ;
  a skos:Concept .

<https://concepts.sagepub.com/social-science/concept/treatment_theories,_research,_techniques,_strategies,_and_effectiveness>
  skos:prefLabel "treatment theories, research, techniques, strategies, and effectiveness"@en ;
  a skos:Concept ;
  skos:narrower <https://concepts.sagepub.com/social-science/concept/levo-alpha_acetyl_methadol> .